iifl-logo-icon 1

Astrazeneca Pharma India Ltd Share Price

6,434.85
(-0.27%)
Jul 19, 2024|09:44:55 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open6,469.8
  • Day's High6,510.3
  • 52 Wk High7,572.2
  • Prev. Close6,452.05
  • Day's Low6,400
  • 52 Wk Low3,749.8
  • Turnover (lac)50.32
  • P/E108.05
  • Face Value2
  • Book Value284.77
  • EPS59.63
  • Mkt. Cap (Cr.)16,087.13
  • Div. Yield0.37
No Records Found

Astrazeneca Pharma India Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

6,469.8

Prev. Close

6,452.05

Turnover(Lac.)

50.32

Day's High

6,510.3

Day's Low

6,400

52 Week's High

7,572.2

52 Week's Low

3,749.8

Book Value

284.77

Face Value

2

Mkt Cap (₹ Cr.)

16,087.13

P/E

108.05

EPS

59.63

Divi. Yield

0.37

Astrazeneca Pharma India Ltd Corporate Action

22 Jul 2023

12:00 AM

AGM

Announcement Date: 22 Jul, 2023

arrow

27 May 2024

12:00 AM

Dividend

Dividend Amount: 24

Record Date: 05 Jul, 2024

arrow

15 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Astrazeneca Pharma India Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Astrazeneca Pharma India Ltd SHAREHOLDING SNAPSHOT

20 Jul, 2024|02:21 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 75.00%

Foreign: 0.00%

Indian: 75.00%

Non-Promoter- 6.51%

Institutions: 6.51%

Non-Institutions: 18.48%

Custodian: 0.00%

Share Price

Astrazeneca Pharma India Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

5

5

5

5

Preference Capital

0

0

0

0

Reserves

706.92

583.69

506.39

451.17

Net Worth

711.92

588.69

511.39

456.17

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

805.6

813.56

831.81

571

yoy growth (%)

-0.97

-2.19

45.67

5.01

Raw materials

-311.96

-294.95

-305.23

-181.09

As % of sales

38.72

36.25

36.69

31.71

Employee costs

-230.21

-219.54

-216.7

-153.53

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

83.04

127.09

113.97

43.8

Depreciation

-16.95

-20.13

-18.58

-14.74

Tax paid

-21.44

-33.79

-41.76

-17.89

Working capital

57.86

101.15

103.65

52.76

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-0.97

-2.19

45.67

5.01

Op profit growth

-36.38

12.23

160.74

25.31

EBIT growth

-34.47

11.35

162.8

23.38

Net profit growth

-33.97

29.2

178.69

29.22

View Ratios

No Record found

Astrazeneca Pharma India Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,594.25

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,584.8

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.65

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.65

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,667.5

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Astrazeneca Pharma India Ltd

Management

Register Office

Registrar Office

Chairman & Independent Directo

Narayan K Seshadri

Non-Exec. & Independent Dir.

Revathy Ashok

Whole Time Director & CFO

Rajesh Marwaha.

Non Executive Director

Weiying Sarah Wang

Non Executive Director

Ankush Nandra

Non-Exec. & Independent Dir.

Shilpa Divekar Nirula

Managing Director

Sanjeev Panchal

Non Executive Director

Hooi Bien Chuah

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Companys issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.The company expanded the installed capacity of Injectables during the year 2001 by 0.20 crores (Nos) and with this expansion the total capacity has been increased to 2.40 crores (Nos).The Companys marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has commiss
Read More

Company FAQs

What is the Astrazeneca Pharma India Ltd share price today?

Down Arrow

The Astrazeneca Pharma India Ltd shares price on N/A is Rs.₹6453.15 today.

What is the Market Cap of Astrazeneca Pharma India Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd is ₹16132.88 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Astrazeneca Pharma India Ltd?

Down Arrow

The PE and PB ratios of Astrazeneca Pharma India Ltd is 108.05 and 22.62 as of 19 Jul ‘24

What is the 52 Week High and Low of Astrazeneca Pharma India Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Astrazeneca Pharma India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Astrazeneca Pharma India Ltd is ₹3730 and ₹7550 as of 19 Jul ‘24

What is the CAGR of Astrazeneca Pharma India Ltd?

Down Arrow

Astrazeneca Pharma India Ltd's CAGR for 5 Years at 26.96%, 3 Years at 22.53%, 1 Year at 70.48%, 6 Month at 2.16%, 3 Month at 23.79% and 1 Month at 0.11%.

What is the shareholding pattern of Astrazeneca Pharma India Ltd?

Down Arrow

The shareholding pattern of Astrazeneca Pharma India Ltd is as follows:
Promoters - 75.00 %
Institutions - 6.52 %
Public - 18.48 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.